Home / Clinical areas / Oncology

Oncology

Sequencing Panels

Oncohematology

Myeloproliferative neoplasms
  • Polycythemia vera – JAK2 (exon 12) [1 gene]

    Ref.: S-202008868|Turnaround time (TAT) 25 days

  • Detection of the mutations c.1544G>T (p.Trp515Leu) and c.1514G>A (p.Ser505Asn) in MPL gene [1 gene]

    Ref.: S-202212470|Turnaround time (TAT) 20 days

  • Exon 9 in CALR gene [1 gene]

    Ref.: S-202212296|Turnaround time (TAT) 20 days

  • Detection of BCR/ABL1 rearrangement [2 genes]

    Ref.: S-202212976|Turnaround time (TAT) 6 days

  • Quantification of BCR/ABL1 rearrangement [2 genes]

    Ref.: S-202212446|Turnaround time (TAT) 6 days

  • Detection of the p.T618I mutation in CSF3R gene [1 gene]

    Ref.: S-202009668|Turnaround time (TAT) 20 days

  • Detection of the D816V mutation in c-KIT gene [1 gene]

    Ref.: S-202009330|Turnaround time (TAT) 20 days

Myeloid and lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, or FGFR1 anomalies
  • Detection of FIP1L1/PDGFRA rearrangement [2 genes]

    Ref.: S-202110214|Turnaround time (TAT) 6 days

Myelodysplastic syndromes
  • Myelodysplastic syndrome: K700E mutation in SF3B1 gene [1 gene]

    Ref.: S-202009328|Turnaround time (TAT) 20 days

  • Myelodysplastic syndrome: sequencing of TP53 gene [1 gene]

    Ref.: S-202009329|Turnaround time (TAT) 25 days

  • Myelodysplastic syndrome: MLPA of TP53 gene [1 gene]

    Ref.: S-202009669|Turnaround time (TAT) 20 days

Acute myeloid leukemias
  • Detection of PML/RARa rearrangement [2 genes]

    Ref.: S-202212447|Turnaround time (TAT) 20 days

  • Quantification of PML/RARa rearrangement [2 genes]

    Ref.: S-202212844|Turnaround time (TAT) 20 days

  • Detection of AML1/ETO rearrangement [2 genes]

    Ref.: S-202313411|Turnaround time (TAT) 20 days

  • Quantification of AML1/ETO rearrangement [2 genes]

    Ref.: S-202313407|Turnaround time (TAT) 20 days

  • Mutations in NPM1 gene (exon 12) [1 gene]

    Ref.: S-202009326|Turnaround time (TAT) 20 days

Lymphoblastic leukemias
  • B-cell clonality [B-cell clonality]

    Ref.: S-202212919|Turnaround time (TAT) 6 days

  • T-cell clonality [T-cell clonality]

    Ref.: S-202212920|Turnaround time (TAT) 6 days

Acute lymphoblastic leukemia
  • Detection of TEL/AML1 rearrangement [2 genes]

    Ref.: S-202313408|Turnaround time (TAT) 20 days

  • Detection of MLL/AF4 rearrangement [2 genes]

    Ref.: S-202212457|Turnaround time (TAT) 20 days

Lymphomas
  • IgH/BCL2 t(14;18) rearrangement [2 genes]

    Ref.: S-202313409|Turnaround time (TAT) 25 days

  • CCND1/IgH t(11;14) rearrangement [2 genes]

    Ref.: S-202313410|Turnaround time (TAT) 25 days

Waldenström macroglobulinemia
  • Macroglobulinemia: p.L265P mutation in MYD88 gene [1 gene]

    Ref.: S-202009332|Turnaround time (TAT) 25 days

  • Macroglobulinemia: CXCR4 gene sequencing [1 gene]

    Ref.: S-202009331|Turnaround time (TAT) 25 days

  • Screening of informative marker for chimerism [RT-PCR]

    Ref.: S-202212380|Turnaround time (TAT) 5 days

  • Monitoring of chimerisms via dPCR [RT-PCR]

    Ref.: S-202212381|Turnaround time (TAT) 5 days

Inés Calabria, PhD

Head of the area of Oncology

Informed consent form Steps to follow Need counseling?
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Monday–Friday: 8am – 5pm

5. Result: the report

Via: e-mail and/or through the customer portal

Ask us for more information on our oncology services

"*" indicates required fields

Consentimiento*
This field is for validation purposes and should be left unchanged.
Global panel of oncohematological diseases – Haematology OncoKitDx – 76 genes

ARID5B, ASXL1, ASXL2, ATRX, BCOR, BCORL1, BLNK, BRAF, CALR, CBL, CDKN2A, CDKN2B, CEBPA, CHIC2, CREBBP, CSF3R, CSNK1A1, CUX1, DDX3X, DDX41, DNMT3A, EP300, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2 (+I4), GATA3, HAVCR2, IDH1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KIT, KMT2A, KMT2C, KRAS, MPL, NF1, NFE2, NOTCH1, NPM1, NR3C1, NRAS, P2RY8, PAX5, PHF6, PIGA, PPM1D, PTEN, PTK2B, PTPN11, RAD21, RB1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRP72, SRSF2, STAG1, STAG2, STAT5B, TET2, TP53, TYK2, U2AF1, WT1, ZRSR2

Polycythemia vera – JAK2 (exon 12) – 1 gene

JAK2

Detection of the mutations c.1544G>T (p.Trp515Leu) and c.1514G>A (p.Ser505Asn) in MPL gene – 1 gene

MPL

Exon 9 in CALR gene – 1 gene

CALR

Detection of BCR/ABL1 rearrangement – 2 genes

ABL1/BCR

Quantification of BCR/ABL1 rearrangement – 2 genes

ABL1/BCR

Detection of the p.T618I mutation in CSF3R gene – 1 gene

CSF3R

Detection of the D816V mutation in c-KIT gene – 1 gene

c-KIT

Detection of FIP1L1/PDGFRA rearrangement – 2 genes

FIP1L1/PDGFRA

Myelodysplastic syndrome: K700E mutation in SF3B1 gene – 1 gene

SF3B1

Myelodysplastic syndrome: sequencing of TP53 gene – 1 gene

TP53

Myelodysplastic syndrome: MLPA of TP53 gene – 1 gene

TP53

Detection of PML/RARa rearrangement – 2 genes

PML/RARa

Quantification of PML/RARa rearrangement – 2 genes

PML/RARa

Detection of AML1/ETO rearrangement – 2 genes

AML1/ETO

Quantification of AML1/ETO rearrangement – 2 genes

AML1/ETO

Mutations in NPM1 gene (exon 12) – 1 gene

NPM1

Detection of TEL/AML1 rearrangement – 2 genes

TEL/AML1

Detection of MLL/AF4 rearrangement – 2 genes

TEL/AML1

IgH/BCL2 t(14;18) rearrangement – 2 genes

IgH/BCL2 t(14;18)

CCND1/IgH t(11;14) rearrangement – 2 genes

CCND1/IgH t(11;14)

Macroglobulinemia: p.L265P mutation in MYD88 gene – 1 gene

MYD88

Macroglobulinemia: CXCR4 gene sequencing – 1 gene

CXCR4